Update: SS Innovations Launches Innovative Robotic Cardiac Surgery Program in India
- Launch of innovative cardiac surgery program in India
- Over 20 successful surgeries performed
- Plans to expand internationally
- World's first beating heart robotic cardiac bypass surgery performed
- None.
Dr. Sudhir Srivastava, a world-leading cardiac surgeon, performed the world’s first beating heart robotic cardiac bypass surgery using the SSi Mantra Surgical Robotic System
FORT LAUDERDALE, FL, Oct. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announces the launch of an innovative robotic cardiac surgery program in India utilizing its flagship SSi Mantra surgical robotic system.
The company’s cardiac program aims to revive and invigorate the field of robotic coronary artery bypass and intracardiac surgery in India, and to train surgeons throughout the country in these procedures using the SSi Mantra. More than 20 robotic cardiac surgeries have been successfully performed using SS Innovations’ surgical robotic system in India, to date.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, said, “Each year more than 2,000,000 open heart surgeries are performed globally, however in India, doctors perform approximately 100,000 surgeries annually. Additionally, today more than
“While in the USA, I helped develop many ‘World’s First’ cardiac bypass procedures that avoided such invasive approaches. Most of my cardiac bypass patients went home in just 3 days or less. The results were outstanding. It is high time that we utilize technology to its fullest potential. It was always my goal to revive robotic cardiac surgery and while developing the Mantra Surgical Robotic System; I was acutely aware of how our platform would always include cardiac surgery as a viable treatment option for many patients globally. Every patient should have access to gold standard surgical care, and we believe that our cost-effective surgical robotic system is a key part of the solution.
“SS Innovations plans to launch multiple robotic cardiac surgical programs throughout India, followed by programs internationally. Joined by many global leaders in cardiac surgery who are part of our International Cardiac Advisory Board, we collectively believe there is an enormous opportunity to address the significant unmet need for safe, timely, and affordable cardiac surgical care around the world.”
In September 2023, Dr. Srivastava, a world-leading cardiac surgeon, performed the world’s first beating heart robotic cardiac bypass surgery using the SSi Mantra. The Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB) is one of the most complex surgical approaches in Cardiac Surgery. It is a minimally invasive procedure that is performed on a beating heart, through tiny ports, in a closed chest, without the need for a cardiopulmonary bypass machine.
Dr. Srivastava has completed more than 1,400 robotic cardiothoracic surgical procedures, including 750 TECAB cases.
The SSi Mantra Surgical Robotic System is the first surgical system to be made in India, and one of the only systems in the world to be distinctly cost-effective with broad-spectrum surgical applications including cardiac surgery. The Mantra System has been granted regulatory approval in India and is clinically validated in more than 40 different types of surgical procedures. SS Innovations expects to secure regulatory approvals in the United States and Europe in 2024 and 2025.
About SS Innovations International, Inc.
SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra”, its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at ssinnovations.com or LinkedIn for updates.
About SSi Mantra
Supporting advanced, affordable, and accessible robotic surgery, the SSi Mantra Surgical Robotic System provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and more. With its modular, 3D vision open-console design and superior ergonomics, the system engages machine learning models to improve safety and efficiency during procedures. The SSi Mantra system has received Indian Medical Device regulatory approval (CDSCO) and is clinically validated in India in more than 40 different surgical procedures. The company expects to seek regulatory approvals from the US Food and Drug Administration (FDA) and CE Mark in Europe in 2023 and 2024.
Forward-Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations International’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
For more information:
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341
